| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P J Blanchet, S Konitsiotis, T N Chas. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. The Journal of pharmacology and experimental therapeutics. vol 283. issue 2. 1997-12-08. PMID:9353400. |
potent, selective, short-acting dopamine d2 receptor subfamily agonists show good antiparkinsonian efficacy but produce dyskinesias comparable to levodopa. |
1997-12-08 |
2023-08-12 |
monkey |
| P J Blanchet, S Konitsiotis, T N Chas. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. The Journal of pharmacology and experimental therapeutics. vol 283. issue 2. 1997-12-08. PMID:9353400. |
to clarify this issue, we compared the nonselective dopamine d1/d2 receptor subfamilies agonist apomorphine to the dopamine d3 receptor preferring agonist [r-(+)-trans-3,4,4a,10b-tetrahydro-4-propyl-2h,5h-[1]benzopyrano[4 , 3-b]-1,4-oxazin-9-ol] (pd 128,907) in 6 levodopa-primed , 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian monkeys with reproducible dyskinesias. |
1997-12-08 |
2023-08-12 |
monkey |
| M Contin, R Riva, P Martinelli, F Albani, A Baruzz. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study. Clinical neuropharmacology. vol 20. issue 5. 1997-12-02. PMID:9331517. |
these data suggest a dissociation of the kinetic-dynamic relationship of l-dopa motor and dyskinesia effects, possibly reflecting different cerebral handling of exogenous levodopa-derived dopamine with disease progression. |
1997-12-02 |
2023-08-12 |
Not clear |
| S Kun. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications. European neurology. vol 38 Suppl 1. 1997-10-16. PMID:9276196. |
l-dopa, the precursor of dopamine, remains most effective in the treatment of patients with parkinson's disease, but prolonged l-dopa treatment often produces adverse effects, including dyskinesia and psychosis. |
1997-10-16 |
2023-08-12 |
monkey |
| N Turjanski, A J Lees, D J Brook. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. vol 49. issue 3. 1997-10-10. PMID:9305330. |
in vivo studies on striatal dopamine d1 and d2 site binding in l-dopa-treated parkinson's disease patients with and without dyskinesias. |
1997-10-10 |
2023-08-12 |
Not clear |
| I L Brin, K V Mashilo. [The effect of low doses of nakom on the hormonal secretion of the hypothalamo-hypophyseal-adrenal system in patients with infantile cerebral palsy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 96. issue 4. 1997-09-03. PMID:9281279. |
hyperkinetic phenomena revealed the connection between the character of neuromotor dyskinesias and the state of hypothalamo-hypophyseal-adrenal axis which is regulated by dopamine. |
1997-09-03 |
2023-08-12 |
Not clear |
| R L Watt. The role of dopamine agonists in early Parkinson's disease. Neurology. vol 49. issue 1 Suppl 1. 1997-08-04. PMID:9222273. |
dopamine agonists, when used alone, rarely promote the development of dyskinesias and motor fluctuations that complicate levodopa treatment. |
1997-08-04 |
2023-08-12 |
Not clear |
| G J Fici, H Wu, P F VonVoigtlander, V H Seth. D1 dopamine receptor activity of anti-parkinsonian drugs. Life sciences. vol 60. issue 18. 1997-05-16. PMID:9126882. |
clinical and preclinical investigations suggest that stimulation of d1 dopamine receptors may be responsible for dyskinesias induced by dopamine agonist treatment of parkinson's disease (pd), and that these dyskinesias may be decreased by treatment with a d1 antagonist (clozapine). |
1997-05-16 |
2023-08-12 |
Not clear |
| F Durif, M Vidailhet, F Assal, C Roche, A M Bonnet, Y Agi. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology. vol 48. issue 3. 1997-03-28. PMID:9065543. |
the severity of parkinsonian motor disability and dyskinesias was evaluated in seven levodopa-responsive patients with parkinson's disease after an acute challenge with the mixed dopamine agonist apomorphine, before and after low-dose clozapine (50 mg) for 18 +/- 2 days. |
1997-03-28 |
2023-08-12 |
Not clear |
| J L Neisewander, E Castañeda, D A Davis, H J Elson, A N Sussma. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. European journal of pharmacology. vol 305. issue 1-3. 1997-02-20. PMID:8813526. |
the present study examined whether reserpine-induced oral dyskinesia is mediated by release of residual endogenous dopamine. |
1997-02-20 |
2023-08-12 |
Not clear |
| M Goulet, R Grondin, P J Blanchet, P J Bédard, T Di Paol. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain research. vol 719. issue 1-2. 1997-02-04. PMID:8782872. |
however, dyskinesia occurred in two monkeys which had striatal dopamine depletion of > 99% compared to the non-dyskinetic animal slightly less denervated (94%). |
1997-02-04 |
2023-08-12 |
monkey |
| P J Blanchet, P Allard, L Grégoire, F Tardif, P J Bédar. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 23. issue 3. 1997-01-06. PMID:8862840. |
no clinical parameter other than "sufficient" dopamine denervation and exposure to exogenous levodopa has been unquestionably linked to dyskinesia in levodopa-treated parkinson's disease patients. |
1997-01-06 |
2023-08-12 |
Not clear |
| R Bossé, T DiPaol. The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cellular and molecular neurobiology. vol 16. issue 2. 1996-11-14. PMID:8743969. |
the present data suggest that gonadal hormone withdrawal by reducing brain dopamine receptors and producing an imbalance of gabaa receptors in the output pathways of the striatum may predispose to schizophrenia and dyskinesia. |
1996-11-14 |
2023-08-12 |
rat |
| P J Blanchet, B Gomez-Mancilla, P J Bédar. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Journal of neural transmission. Supplementum. vol 45. 1996-10-23. PMID:8748615. |
dopa-induced "peak dose" dyskinesia (did) observed during the treatment of parkinson's disease patients has traditionally been linked primarily to dopamine d1 receptor-mediated mechanisms. |
1996-10-23 |
2023-08-12 |
monkey |
| P J Blanchet, B Gomez-Mancilla, P J Bédar. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Journal of neural transmission. Supplementum. vol 45. 1996-10-23. PMID:8748615. |
however, in mptp-induced parkinsonian monkeys with did, the administration of selective dopamine d1 or d2 agonists will, in the case of d1 agonists result in similar antiparkinsonian effect but with much less dyskinesia. |
1996-10-23 |
2023-08-12 |
monkey |
| R K Pearce, M Jackson, L Smith, P Jenner, C D Marsde. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Movement disorders : official journal of the Movement Disorder Society. vol 10. issue 6. 1996-09-27. PMID:8749992. |
the mptp-treated marmoset provides a useful model in which to study dyskinesias in parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy. |
1996-09-27 |
2023-08-12 |
marmoset |
| P J Blanchet, R Grondin, P J Bédar. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Movement disorders : official journal of the Movement Disorder Society. vol 11. issue 1. 1996-09-26. PMID:8771074. |
dyskinesia and wearing-off following dopamine d1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. |
1996-09-26 |
2023-08-12 |
monkey |
| H Lubli. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia. Clinical neuropharmacology. vol 18. issue 6. 1996-08-19. PMID:8681313. |
eight cebus apella monkeys previously treated with dopamine d1 and d2 receptor antagonists were used to elucidate the pathophysiology of acute oral dyskinesia. |
1996-08-19 |
2023-08-12 |
monkey |
| G L Defer, C Geny, F Ricolfi, G Fenelon, J C Monfort, P Remy, G Villafane, R Jeny, Y Samson, Y Keravel, A Gaston, J D Degos, M Peschanski, P Cesaro, J P Nguye. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain : a journal of neurology. vol 119 ( Pt 1). 1996-06-25. PMID:8624693. |
the occurrence of dyskinesias might simply reflect increased presynaptic storage and release of dopamine. |
1996-06-25 |
2023-08-12 |
Not clear |
| P J Blanchet, B Gomez-Mancilla, T Di Paolo, P J Bédar. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fundamental & clinical pharmacology. vol 9. issue 5. 1996-06-12. PMID:8617407. |
thus far, indirect clinical and experimental evidence has implicated the potential role of dopamine d1 receptor activation in the generation of dopa dyskinesia. |
1996-06-12 |
2023-08-12 |
monkey |